This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free ...
An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European ...
An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency ...
Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
The prime editor is a fusion protein consisting of a catalytically impaired Cas9 nickase (Cas9n) and an engineered reverse transcriptase (RT). The Cas9n is guided by a prime editing guide RNA (pegRNA) ...
Researchers at the Broad Institute and The Jackson Laboratory have used prime editing, a precise and versatile form of gene editing, to correct the root cause of AHC in mice. The team used a scalable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results